"Special K" is getting the "one over" by The Food and Drug Administration of America.
The Food and Drug Administration is hoping a little experimentation on the wrong side of the tracks will pay dividends. Ketamine, which is consumed at a high rate by partygoers short on Coke money, will be used in a clinical study for depression.
Mark Wilson/Getty Images
But it isn't Ketamine-proper that will be used in the new beta treatment, but a "chemical cousin" of the drug called Esketamine. As far as the medical community is concerned, it's only partially responsible for the "Esketit" epidemic first generated by Lil Pump and Smokepurpp.
The FDA's decision to implement Esketamine came after a month of weighing its cost-benefit ratio, all within the better judgment of a panel of experts, plucked from different sectors of the Pharmaceutical World.
"There has been a long-standing need for additional effective treatments for treatment-resistant depression, a serious and life-threatening condition," says Dr. Tiffany Farchionem, a high ranking official in the FDA. The organization eventually issued a press release in which Farchionem is on the hook for much of the careful wording.
"This is potentially a game changer for millions of people," added Dr. Dennis Charney, the headmaster at the Icahn School of Medicine at Mount Sinai in New York. "It offers a lot of hope."
With Esketamine on the agenda, the FDA hopes they can fill the deficiencies posed by drugs like Prozac. The FDA is also hopeful Esketamine might prove advantageous for all the sufferers of clinical depression who have yet to find an answer to their symptomology.